UK Life Sciences Company Directory

High-capacity viral vector manufacturing platform for gene therapy

Icosphere Biosciences is a biotechnology company developing manufacturing technology for high-capacity gene therapy vectors. Its platform enables scalable, high-yield, contamination-free production of high capacity adenoviral vectors capable of carrying substantially more genetic material than conventional viral…

Ubiquitin research reagents and enzyme profiling services

Ubiquigent+ is a research reagent and assay service offering operated within the University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Unit. It supplies antibodies, enzymes, proteins and DNA reagents for studying the ubiquitin system, alongside biochemical profiling services for deubiquitylases and…

GMP/GLP contract microbiology testing for pharma and medical devices

Wickham Micro is a GMP/GLP compliant contract testing laboratory providing microbiology services to the pharmaceutical and medical device industries. Services include sterility, bioburden, bacterial endotoxin and cytotoxicity testing, microbial identification, method validation and environmental monitoring, supporting…

Multi-organism toxicology research and alternative chemical safety testing

PrecisionTox is a University of Birmingham-led international research consortium developing alternative approaches to chemical safety assessment. Its scientists compare molecular toxicity responses across diverse experimental organisms and human cell systems, integrating genomics, metabolomics and computational…

Immuno-oncology therapies targeting the nfP2X7 cancer receptor

Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform. The nfP2X7 receptor is a non-functional form of P2X7 expressed on cancer cells across a broad range of tumour types, enabling targeted therapeutic approaches. The pipeline…

Synthetic plant metabolites for osteoarthritis and age-related disease

AKL Therapeutics is a privately held UK pharmaceutical company developing APPA, a patented oral investigational medicine combining two synthetic plant metabolites that act synergistically to target multiple signalling pathways in osteoarthritis. Animal studies have demonstrated pain reduction and delayed cartilage…

Novel methylation amplification platform for clinical genomic diagnostics

Syndex Bio is a Cambridge-based biotechnology company developing a proprietary platform technology that enables amplification of DNA methylation for the first time. Unlike conventional PCR, which cannot preserve 5-methylcytosine signals, mcPCR copies both the four-base DNA code and its methylation patterns from…

Pre-cancer intervention to prevent cancer before it develops

Omos Biosciences is an early-stage biotechnology company developing approaches to cancer prevention through intervention at the pre-cancerous stage, rather than treatment of established disease. The company's strategy builds on established precedents in early cancer prevention, such as polyp removal to prevent…

AI knowledge graph platform curating biomedical literature for drug discovery

Biorelate is a software company providing AI-driven biomedical data curation to the pharmaceutical and life sciences industry. Its platform applies natural language processing and machine learning to extract structured cause-and-effect relationships from over 30 million scientific text sources, generating knowledge…

Inhaled lentiviral gene therapies for rare respiratory diseases

AlveoGene is a biotechnology company developing inhaled gene therapies for rare respiratory disorders. It uses a lentiviral vector platform engineered to deliver therapeutic genes efficiently to the cells lining the airways and lungs. Its lead programme targets alpha-1 antitrypsin deficiency, an inherited condition…

IgE and IgA antibody therapeutics for cancer treatment

Epsilogen is a clinical-stage biotech pioneering the development of non-IgG immunoglobulin antibody therapeutics for cancer. The company's platform spans IgE, IgA, and IgG isotypes, enabling selection of the most appropriate antibody format for a given tumour type. Its lead candidate MOv18 IgE, the first IgE antibody…

Recombinant Fc receptors for antibody research and development

Gamma Proteins is a Durham-based reagent company supplying recombinant Fc receptors for antibody research and biopharmaceutical development. Its catalogue includes Fc gamma receptors and neonatal Fc receptor (FcRn), with human and selected animal proteins offered in unconjugated and biotinylated formats. The proteins…

Finnish pharma company marketing and developing medicines

Orion Pharma (UK) Limited is the UK subsidiary of Orion Corporation, a Finnish pharmaceutical company. The UK entity manages commercial operations for Orion's prescription medicines portfolio across therapy areas including neurology, respiratory disease, oncology and women's health. A biologics R&D centre opened at…

Oxygen-generating nanoparticles to overcome hypoxia in solid tumours

StimOxyGen is a preclinical-stage biotechnology company developing pH-responsive nanoparticle formulations to address tumour hypoxia, a major barrier to effective cancer treatment. The technology uses a biodegradable polymer coating that dissolves in the acidic tumour microenvironment, transiently generating localised…

Next-generation ADC linker chemistry for precision cancer therapeutics

Siftr Bio is a biotechnology company developing novel linker chemistry for antibody-drug conjugates. Current ADC linkers have limited diversity and insufficient selectivity, contributing to off-target toxicity that restricts their therapeutic application. Siftr's platform screens enzyme-responsive linker candidates…

Global biopharma focused on severe neurological and immunological diseases

UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological diseases. The UK operation is one of UCB's three global R&D hubs, with capabilities spanning antibody discovery, small molecule development,…

Personalised cancer treatment selection using in vivo drug screening

Vivan Therapeutics is a London-based biotech developing a personalised cancer therapeutics platform. The company's Personal Discovery Process sequences a patient's tumour genome, engineers those mutations into a fruit fly avatar model, and screens thousands of approved drug combinations at high throughput to identify…

AAV gene therapy for Bardet-Biedl syndrome and genetic obesity

Axovia Therapeutics is a biotechnology company developing adeno-associated viral gene therapies for inherited ciliopathies and genetic obesity. Its lead candidate delivers a functional BBS1 gene into retinal cells to investigate treatment of vision loss associated with Bardet-Biedl syndrome. A first-in-human, early…

International centre of excellence in plant science and microbiology

The John Innes Centre is a research institute conducting fundamental, strategic and applied research in plant science and microbiology. The centre studies plant and microbial genetics, genomics and cell biology, applying techniques including CRISPR gene editing to improve crop resilience and food security. It trains…

AI and multi-omics platform for cardiovascular drug target discovery

CardiaTec Biosciences is a Cambridge-based biotech applying artificial intelligence to large-scale multi-omic data to identify novel drug targets for cardiovascular diseases. Its platform integrates data across genomic, epigenomic, transcriptomic, proteomic and metabolomic layers to map disease mechanisms and uncover…